Unity's Q2 FY25 results reveal AI-driven growth, but competition and high valuation raise risks. Click here to find out why I rate U stock a hold.

Enterprise data platforms increasingly unite analytics, governance and orchestration, with new generative and agentic AI-enabled features to improve autonomy and speed.

Unity Software Inc. (U) continues to fire on all cylinders, with the stock up 64% in the past three months, outperforming the industry and the S&P 500’s gains of 11.8% and 10.2%, respectively. Over ...

VectorY Therapeutics has seen the shape of things to come—and it involves finding fresh ways to deliver its gene therapies into the brain. | VectorY Therapeutics has seen the shape of things to ...

Platform enhancements, including the release of Denodo DeepQuery, solidify Denodo as a foundation for AIPALO ALTO, Calif., ...

Zacks Investment Research - Zacks Investment Research - Thu Aug 21, 12:16PM CDT Technical indicators imply U's continued strong performance. The stock is trading above its 50-day moving average, ...

A gene therapy for neovascular age-related macular degeneration in the second eye shows safety and preservation of vision and anatomy a year after the first eye was treated.

Unity Software Inc. has achieved a significant milestone, with its stock reaching a 52-week high of $42.15. With a market capitalization of $16.52 billion and a healthy current ratio of 2.73, the ...